Journal of Clinical Oncology
Articles in this Issue
Genomic characterization of anal canal squamous cell carcinoma (ASCC) and outcomes on matched targeted therapy.
3526 Background: Anal canal squamous cell carcinoma (ASCC) is uncommon but increasing in incidence. 5-year survival of patients (pts) with metastatic ASCC...
Trends in mortality, incidence, and survival of uveal melanoma: A SEER-based retrospective analysis.
e21581 Background: Uveal melanoma (UM) is the most prevalent primary intraocular malignancy in the adults. The age-adjusted incidence of UM in the US is 4...
Eribulin plus pyrotinib In trastuzumab-resistant HER2-positive advanced breast cancer: A single-arm, multicenter phase II trial (EPIC trial).
1031 Background: This study (ChiCTR2000038832) aimed to evaluate the efficacy and safety of combining eribulin with pyrotinib in patients with advanced HE...
Prophylactic dexamethasone (dex) with outpatient step-up dosing (SUD) of bispecific antibodies (BsAb) in multiple myeloma (MM) vs standard of care (SOC) inpatient observation.
e19506 Background: Teclistamab (tec) and talquetamab (tal) are BsAb therapies approved for MM. Due to the risk of CRS and ICANS, the prescribing informati...
Mechanisms of efficacy of endonuclease inhibition in neuroblastoma.
e15108 Background: Children with high-risk and relapsed neuroblastoma (NB) need improved therapies, and recurrent cytogenetic abnormalities, such as...
Esophageal squamous cell carcinoma: Mortality-to-incidence ratio (MIR) and survival trends.
e16135 Background: The most prevalent esophageal cancer globally is esophageal squamous cell carcinoma (ESCC). In the US, 90% of cases are linked to smoki...
Real world safety outcomes of an outpatient lymphoma bispecific antibody program: A single center experience from Johns Hopkins.
e19018 Background: Bispecific Antibodies (BsAb) have demonstrated efficacy in the treatment of patients with hematologic malignancies through leveraging o...
Risk of acute care events: Designing prognostic models for real world use.
e13562 Background: Electronic health records (EHRs) combined with advances in cloud processing and computing power have made prognostic modeling a growth...
Impact of <i>MTAP</i> deletion on immunotherapy outcomes in patients with mesothelioma.
8081 Background: MTAP ( methylthioadenosine phosphorylase ) is located on chromosome 9p21 and often co-deleted with...
Final analysis of SCORES, a phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer.
5554 Background: At the SCORES interim analysis, suvemcitug (a recombinant humanized anti-VEGF rabbit monoclonal antibody) plus chemotherapy demonstrated...
Effectiveness and safety of multimodal analgesic management based on the ERAS concept in the perioperative period of TACE for patients with Intermediate and advanced hepatocellular carcinoma.
12085 Background: To evaluate the effectiveness and safety of multimodal analgesic management based on the enhanced recovery after surgery (ERAS) concept...
Melanoma burden in the US, 1999-2023: Rising incidence, declining mortality, and regional inequities.
e21601 Background: Melanoma remains a significant public health concern in the United States, with rising incidence rates and variable mortality outcomes...
Clinical and biomarker analyses of first-line nivolumab and relatlimab (nivo-rela) in advanced or resectable melanoma (mel).
9535 Background: Simultaneous blockade of lymphocyte activation gene-3 (LAG-3) and programmed death-1 (PD-1) pathways enhances antitumor activity in patie...
Integrated analysis of bulk and single-cell RNA sequencing data to identify an oxidative phosphorylation-based prognostic signature for lung adenocarcinoma.
e20059 Background: Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality globally. Despite treatment advances, challenges for dru...
Impact of elinzanetant on sleep disturbances and quality of life in women undergoing adjuvant endocrine therapy for breast cancer: Phase 3 OASIS 4 trial.
12063 Background: Vasomotor symptoms (VMS) and sleep disturbances are common in women taking adjuvant endocrine therapy (AET) for hormone receptor-positiv...
Efficacy and toxicity of pembrolizumab in addition to neoadjuvant platinum-based chemotherapy (NAPC) in triple-negative breast cancer (TNBC) patients with and without germline BRCA mutations (gBRCAmut).
e12611 Background: TNBC is an aggressive disease with high rates of metastatic recurrence. The addition of Pembrolizumab to NAPC has significantly improve...
Survival and hospitalizations with lutetium (Lu)-177 vipivotide tetraxetan in veterans with underlying genomic alterations.
5068 Background: Lutetium-Lu 177 vipivotide tetraxetan ( 177 Lu-PSMA-617) is a radioligand therapy used to treat metastatic castra...
Multi-cancer risk prediction in asymptomatic adults using urinary glycosaminoglycan profiling.
10522 Background: Current screening guidelines are based on established risk factors such as age and tobacco use. Currently, no biomarker is routinely use...
Impact of smoking on immunotherapy outcomes in cancer: A multi-center retrospective analysis.
e14658 Background: Smoking is a well-established risk factor for cancer progression and treatment-related adverse events. Its influence on immunotherapy o...
A phase II study of C019199 in combination with sintilimab in patients with locally recurrent or metastatic triple negative breast cancer (TNBC).
e13134 Background: C019199 is an oral drug candidate that modulates the tumor micro-environment (TME) through targeting CSF-1R/DDRs/VEGFR2. Previous phase...
Real-world effectiveness and safety with sacituzumab govitecan (SG)–based therapy in metastatic breast cancer (MBC) in China: A multicenter retrospective study.
e13181 Background: SG was approved to treat patients who have received ≥1 prior systemic therapy in metastatic setting with triple-negative (TN) MBC or pr...
Genetic counseling (GC) in the era of next generation sequencing (NGS) to diagnose microsatellite instability (MSI) and deficient mismatch repair (dMMR) expression in colorectal cancer (CRC).
e22597 Background: Hereditary Nonpolyposis Colorectal Cancer (HNPCC), known as Lynch syndrome, is inherited in an autosomal dominant manner, characterized...
Navigating artificial intelligence (AI) accuracy: A meta-analysis of hallucination incidence in large language model (LLM) responses to oncology questions.
e13686 Background: Conversational AI, such as LLM-powered Chat-GPT, provides immediate, human-like responses to oncology questions. However, such LLMs are...
Retrospective review of hereditary leiomyomatosis and renal cell cancer at a single institution.
10621 Background: Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) is an autosomal dominant syndrome caused by loss-of-function mutations in the...
Differences in supportive care service utilization among long term metastatic breast cancer survivors by rurality.
12093 Background: Patients living with metastatic breast cancer (MBC) have unique psychosocial and medical needs, which often go unrecognized. Many patien...